Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELIBORDARA: Selinexor, Bortezomib, Dexamethasone, and Daratumumab in Relapsed/Refractory Multiple Myeloma
NCT03589222Phase 2Active, not recruiting
- Sponsor
- Fundación PETHEMA
- Start
- Jul 2018
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in multiple myeloma (MM), sponsored by Fundación PETHEMA. Started Jul 2018; status: active, not recruiting.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03589222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03589222.